Full-Time

VP of Quality Compliance

Posted on 11/7/2025

Asahi Kasei Corporation

Asahi Kasei Corporation

10,001+ employees

Diversified chemicals, materials, healthcare, housing conglomerate

Compensation Overview

$243k - $260k/yr

+ Health Benefits + 401K employer match + Paid time off + Holidays + Sick Leave

Fremont, CA, USA

In Person

Category
Biology & Biotech (7)
, , , , , ,
Requirements
  • Advanced degree in Pharmaceutics, Biochemistry, Physical Chemistry, Organic Chemistry, Biochemical Engineering, or related experience
  • 20+ years of experience leading and managing large teams in a combination of Quality Compliance, Quality Assurance and Quality system is required
  • Prior experience with monoclonal antibodies and E. coli is required
  • Superb quality decision making skills, sound leadership judgment, and proven communication capabilities, as well as significant experience in the biopharmaceutical industry specifically large molecule, are critical factors for success
  • Complete understanding of the commercialization and commercial requirements of a CDMO, Biologics based process and products in the US
  • Excellent oral and written communication skills, ability to communicate at executive team levels, and proven ability to work autonomously and manage effectively in a matrix environment
  • Articulate, persuasive and demonstrated ability to influence others, while employing sound judgment and good sense
  • Possesses the strongest ethics and integrity
  • Experience with analytical method validation and optimization for drug substance/drug product release and stability testing is required
  • Experience with applying the principles and techniques of analytical chemistry is required
  • Extensive experience and knowledge of GMPs is required
Responsibilities
  • Ensure the success of the Quality Compliance through strategic and tactical leadership
  • Lead the quality organization in the continuous improvement of the quality management plan and serve as the final decision maker for all quality decisions including release of commercial or investigational product for market or clinical distribution, respectively
  • Execute on all aspects of the Quality Management System including but not limited to Audit planning and Execution, Deviations, CAPAs, Change Controls, Good Documentation Practice, cGMP System Validation, Inspection Readiness, Issue Management, Process Development, Risk Management and Training
  • Demonstrated success in evaluating quality compliance issues in all phases of commercial readiness, followed by a recommendation for effectively resolving the business challenge
  • QA aspects of vendor oversight including audits, establishment of Quality Agreements, major deviation review, and batch disposition/release
  • Oversee the planning and conduct of internal and external audits to ensure compliance with regulatory requirements for clinical trials and for investigational drug manufacturing, and ensure corrective actions are implemented to resolve audit findings
  • With the Quality organization and through existing Quality Systems and processes, lead all aspects of required quality support to various product development projects and support progression from Clinical to Commercial (readiness) Programs throughout their lifecycles
  • Establish and maintain a robust compliance audit program that ensures compliance of external and internal functions in the execution of cGMP responsibilities
  • Responsible for leadership of all Quality activities for internal operations as well as for contract manufacturers, contract laboratories, cGMP service providers, consultants, and partners
  • Lead the quality organization in the execution of the quality management plan, ensuring sufficient and appropriate staffing of key and required functions, continued education and development of quality teams, and all aspects of personnel management
  • Create and sustain a positive, safe, and appropriate work environment that engages team members and allows them to sustain a healthy work life balance
  • Serve as final decision maker for all product quality or compliance decisions, including release of materials, intermediates, drug substance and drug products
  • Represent Quality in all executive level interactions, internally and externally with partners, Health Authorities, or in corporate matters
  • Ensure the integration of risk management in compliance and quality
  • Responsible for developing and executing a comprehensive budget for quality operations, both day-to-day and during the company's expansion
  • Work closely with process Development colleagues in establishing appropriate analytical support for dynamic, accelerated process decisions
  • Define and execute on continuous improvement opportunities for QC laboratory to drive efficiencies in operations
  • Establish clear expectations, metrics and KPIs, to monitor business process performance and stability
  • Provide leadership, coaching and guidance to the team
  • Be an effective communicator of ideas, project goals and results to team members across the development and commercial organization
  • Implement and integrate risk management into the quality management of clinical and commercial products
  • Build strong relationships with key cross-functional stakeholders including Clinical Operations and Data Management, CMC (technical operations, supply chain, analytical development), Regulatory and Project Management
  • Oversee the EH&S function
  • Offer expert advice on Quality compliance matters while assisting in the expansion of the company's reach into the Viral Vector and PDNA domains
Asahi Kasei Corporation

Asahi Kasei Corporation

View

Asahi Kasei produces a wide range of products including performance polymers, medical devices, and residential construction materials. The company operates by applying polymer science and engineering to create specific components, such as battery separators for electric vehicles and dialysis equipment for patient care. Unlike many specialized competitors, Asahi Kasei maintains a highly diversified portfolio that spans from basic chemicals to advanced healthcare, allowing it to balance industrial stability with growth in emerging technology sectors. Its goal is to drive global expansion and sustainability by developing materials and services that support carbon neutrality, clean energy, and community health.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1922

Simplify Jobs

Simplify's Take

What believers are saying

  • North Carolina separator capacity targets higher-value coated products from mid-2027.
  • Aicuris acquisition expands antiviral assets for immunocompromised patients.
  • Finland hydrogen electrolyzer deployment strengthens industrial decarbonization positioning.

What critics are saying

  • Canada separator plant delay to 2029 or later defers revenue and utilization.
  • North American EV demand weakness cuts separator demand and undermines expansion economics.
  • Aicuris integration risks delay commercialization, eroding returns on the €780 million purchase.

What makes Asahi Kasei Corporation unique

  • Diversified across Healthcare, Homes, and Material businesses since 1922.
  • Owns battery separators, dialysis devices, and housing materials under one group.
  • Combines advanced chemistry with global manufacturing and approximately 50,352 employees.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Asahi Kasei Corporation who can refer or advise you

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Apr 10th, 2026
Asahi Kasei builds $200M+ US battery separator plant to tap EV boom

Asahi Kasei is expanding its battery separator production in the US with a new Hipore coating facility in North Carolina, targeting growing electric vehicle and energy storage demand. The facility, set to start production in mid-2027, will focus on advanced separator technologies aligned with regional safety standards. The move positions Asahi Kasei closer to North American battery and EV manufacturers, targeting higher-value coated separator products. Shares in TSE:3407 are trading at ¥1,634.5, with a year-to-date return of 15.1% and 78.1% over the past year. The expansion faces execution risks including potential delays and cost overruns, alongside competitive pressure from rivals like Toray, Sumitomo Chemical and SK IE Technology. Financial impact is expected to be phased, allowing time for customer qualification and contract negotiations.

Business Wire
Mar 20th, 2026
Chevron Technology Ventures, Asahi Kasei Invest in Heavy-Industry Robotics Company KEWAZO

KEWAZO, the robotics company transforming heavy industry worldwide, today announced a new funding round backed by Chevron Technology Ventures, Asahi Kasei, B...

Scaffmag Ltd
Mar 19th, 2026
KEWAZO raises $30M to scale lifting robots across industrial sites

KEWAZO, a Munich and Houston-based robotics company, has raised $30 million to expand its lifting robot technology across global industrial sites. The funding round was backed by Chevron Technology Ventures, Asahi Kasei, Schooner Capital and existing investors. The company's flagship product, LIFTBOT, automates vertical material movement and is already operational at over 20 industrial locations across Europe and North America, including refineries, petrochemical plants and power facilities. The technology replaces cranes and manual handling during maintenance and capital projects. Chief executive Artem Kuchukov said demand is driven by the need for practical automation in live industrial environments. The funding will support increased deployment capacity and expansion into additional workflows. KEWAZO is also developing a data platform to improve operational transparency and support further automation.

Business Wire
Mar 18th, 2026
Asahi Kasei, Nippon Steel launch pure titanium recycling for electrolysis cells

Asahi Kasei, Nippon Steel and Nippon Steel Trading have launched a recycling initiative to convert pure titanium scrap from electrolysis cell manufacturing into raw material for new pure titanium. The collaboration aims to reduce environmental impact and enhance material value recovery in the chlor-alkali industry. Pure titanium is used in electrolysis cells' anode side to resist corrosive chlorine, requiring extremely high purity. Asahi Kasei controls the entire process at its Nobeoka site through digital tools to prevent contamination. Nippon Steel Trading collects and processes the scrap, which Nippon Steel then remelts into new pure titanium. The partners plan to increase recycling rates and extend the initiative to other metals used in electrolysis cells, building on Asahi Kasei's precious metals recycling project announced in April 2025.

Business Wire
Mar 12th, 2026
Asahi Kasei installs 1MW electrolyzer at Finland's first commercial hydrogen refueling station

Asahi Kasei has begun installing a containerised 1 MW-class alkaline-water electrolyzer at Finland's first commercial hydrogen refueling station in Jyväskylä. The Aqualyzer-C system will be operated by Cefmof Hydrogen, a subsidiary of the Central Finland Mobility Foundation, with operations scheduled to start in summer 2026. The electrolyzer will produce 400kg of hydrogen daily, sufficient to refill approximately three fuel cell vehicles per hour. The project will support local hydrogen-powered transportation, including fuel cell vehicles and hydrogen buses, and serve as a model for hydrogen utilization in cold climates. Asahi Kasei, which has over 50 years of experience in large-scale industrial electrolysis, added the 1–7.5 MW Aqualyzer-C range to its portfolio in 2024 to meet diverse customer needs across small and large-scale hydrogen projects.

INACTIVE